A short BusinessWorld Online piece on what the newest weight loss pill is called. Little detail is available beyond the title.
Recap by typeshit. Full story at BusinessWorld Online.
A sponsored-style explainer that walks through semaglutide versus tirzepatide and the post-shortage compounding limits, while featuring telehealth company Mochi Health.
Drugs.com
Eligibility usually starts at a BMI of 30, or 27 with a weight-related condition. The piece also covers costs, side effects and why most people stay on these drugs long term.
Good Morning America looks at GLP-1 use spreading from adults to a growing number of teens being treated for obesity.
ABC News' chief medical correspondent walks through the latest Novo Nordisk GLP-1 medication and what sets it apart from drugs already on the market.
He blames a 49ers game day for the uptick, reports no negative side effects so far, and says food noise keeps fading.
The FDA had warned the Cary, North Carolina pharmacy in December 2025 about sterile production problems. Check your vial's lot number and beyond-use date.
Loading…